Ms Fralick, we've heard—and I think we all have an imperfect understanding of this—that there seems to be this very curious way of drug pricing in Canada, such that drug companies publish astronomical list prices that nobody actually pays. Then behind closed doors the pharmaceutical companies negotiate significant discounts—we've heard at this meeting that these are between 50% and 90%—that nobody can ever find out.
Can you explain that as an industry practice and tell us whether you think that's a wise way to come to pharmaceutical pricing in Canada?